Biotech News
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
investors.lyratherapeutics.com2026-05-06 15:10 EST
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing